Human enhancement drugs and the pursuit of perfection;Drogas potenciadoras para la búsqueda de la perfección

Adicciones

Volumn 24, Issue 3, 2012, Pages 185-190

  McVeigh, Jim ^a   Evans Brown, Michael ^a   Bellis, Mark A ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Anabolic; Drugs market; Enhancement; Lifestyle; Public health

Indexed keywords

PERFORMANCE ENHANCING SUBSTANCE;

EDITORIAL; HUMAN; LIFESTYLE;

HUMANS; LIFE STYLE; PERFORMANCE-ENHANCING SUBSTANCES;

EID: 84867594246     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.89     Document Type: Article

References (20)

1. Berridge, V. (1978). Victorian opium eating: responses to opiate use in nineteenth-century England. Victorian Studies, 21, 437-461.
2. British Medical Association (1909). Secret remedies. What they cost and what they contain. London: British Medical Association.
3. Chan, T. Y. K. (2009) Outbreaks of severe hypoglycaemia due to illegal sexual enhancement products containing undeclared glibenclamide. Pharmacoepidemiology & Drug Safety, 18, 1.250-1.251.
4. Conrad, P. (2007) The medicalization of society: on the transformation of human conditions into treatable disorders. Baltimore: Johns Hopkins University Press.
5. Evans-Brown, M., Dawson, R. T., Chandler, M., & McVeigh, J. (2009) Use of melanotan I and II in the general population. BMJ, 338: b566.
6. Evans-Brown, M. & McVeigh, J. (2009) Injecting human growth hormone as a performance-enhancing drug-perspectives from the United Kingdom. Journal of Substance Use, 14, 267-288.
7. Evans-Brown, M., Kimergård, A., & McVeigh, J. (2009) Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market. Drug Test Analysis, 1, 323-326.
8. Evans-Brown, M., McVeigh, J., Perkins, C., & Bellis, M. A. (2012) Human enhancement drugs: The emerging challenges to public health. Liverpool: Public Health Observatories in England.
9. Fraser, R., Gower, D. B., Honour, J. W., Ingram, M. C., Kicman, A. T., Makin, H. L. J., & Stewart, P. M. (2010) Analysis of corticosteroids. Steroid Analysis (2nd Edition). Springer.
10. Geiling, E. M. K., & Cannon, P. R. (1938) Pathologic effects of elixir of sulfanilamide (diethylene glycol poisoning). A clinical and experimental correlation: final report. JAMA, 111, 919-26.
11. Lau, G., Lo, D. S., Yao, Y. J., Leonh, H. T., Chan, C. L., & Chu, S. S. (2004) A fatal case of hepatic failure possibly induced by nitrosofenfluramine: a case report. Medicine, Science and the Law, 44, 252-63.
12. National Audit Office (2003), Safety, quality, efficacy: regulating medicines in the UK. London: The Stationery Office.
13. Oliveira, D. B., Foster, G., Savill, J., Syme, P. D., & Taylor, A. (1987) Membranous nephropathy caused by mercury-containing skin lightening cream. Postgraduate Medical Journal, 63, 303-304.
14. Savulescu, J., ter Meulen, R., & Kahane, G. (Eds) (2011) Enhancing human capacities. Oxford: Wiley-Blackwell.
15. Schnetzler, G., Banks, I., Kirby, M., Zou, K. H., & Symonds, T. (2010) Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. Journal of Sexual Medicine, 7, 1237-46.
16. Stalinon: a therapeutic disaster (1958) BMJ. 1:515.
17. Working Party on Amphetamine Preparations (1968). Report of the Working Party on amphetamine preparations. British Medical Association: London.
18. World Health Organization (2004) WHO medicines strategy 2004-2007. Countries at the core. Geneva: World Health Organization.
19. ndedit.). Geneva: World Health Organization.
20. Young, J. H. (1992) The medical messiahs: a social history of health quackery in Twentieth-Century America. Princeton: Princeton University Press.